

Chronix Biomedical to Present Clinical Data on Its Cell-Free DNA Approach as an Early Predictor of Response to Chemotherapy at the AACR Annual Meeting

March 17, 2016 03:00 AM Eastern Daylight Time

SAN JOSE, Calif. & GÖTTINGEN, Germany--([BUSINESS WIRE](#))--Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today announces that it will present data relating to its cell-free DNA copy number instability (CNI) diagnostic at the American Association for Cancer Research ('AACR') Annual Meeting 2016 in New Orleans, Louisiana on 19 April 2016.

The following abstract will be presented during the poster session:

Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers ([see link](#))

The study was conducted by Dr. Glen Weiss and colleagues at Cancer Treatment Centers of America® at Western Regional Medical Center in Goodyear, AZ.

The abstract is scheduled to be presented from 08:00-12:00 CDT on Tuesday, 19 April 2016 at the AACR 2016 conference.

AACR 2016 will take place on 16-20 April 2016 at the Ernest N. Morial Convention Center, New Orleans, Louisiana, USA.

About AACR Annual Meeting 2016

The AACR Annual Meeting is an event for cancer researchers and the broader cancer community. This year's theme, "Delivering Cures Through Cancer Science," reinforces the inextricable link between research and advances in patient care. The theme will be evident throughout the meeting as the latest, most exciting discoveries are presented in every area of cancer research. There will be a number of presentations that include exciting new data from cutting-edge clinical trials as well as companion presentations that spotlight the science behind the trials and implications for delivering improved care to patients.

This cross-cutting, multidisciplinary program will include an outstanding roster of speakers, hundreds of invited talks, and more than 6,000 proffered papers from researchers around the globe. As always, the diversity of the AACR Annual Meeting program will give presenters a forum to share critical updates in all areas, as well as members of the audience an opportunity to actively participate in discussions with colleagues.

About Cancer Treatment Centers of America®

Cancer Treatment Centers of America Global, Inc. (CTCA), headquartered in Boca Raton, Fla., is a national network of five hospitals that serves adult patients who are fighting cancer. CTCA® offers an integrative approach to care that combines advancements in genomic testing and

precision cancer treatment, surgery, radiation, immunotherapy and chemotherapy, with evidence-based supportive therapies designed to help patients physically and emotionally by enhancing their quality of life while reducing side effects both during and after treatment. CTCA serves patients from around the world at its hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Consistently rated among U.S. hospitals that deliver the highest quality of care and patient experience, CTCA provides patients and their families with comprehensive information about their treatment options and encourages their active participation in treatment decisions. For more information, visit cancercenter.com, Facebook.com/cancercenter and Twitter.com/cancercenter.

About Chronix Biomedical

Chronix Biomedical, Inc. is a US-based molecular diagnostics company developing blood tests primarily for the screening and monitoring of cancer. Chronix already offers prognostic tests based on copy number instability for breast and prostate cancer through its own certified laboratories in Göttingen. The prostate cancer test can discriminate between prostate cancer and other prostate conditions (such as benign prostatic hypertrophy and prostatitis) thereby avoiding invasive needle biopsies. These Chronix supplementary tests assist oncologists in making cancer diagnoses and can reduce costs to healthcare providers by preventing unnecessary procedures such as tissue biopsies. For more information visit www.chronixbiomedical.com.

Contacts

Chronix Biomedical, Inc

Dr Howard Urnovitz, CEO, +1 408-960-2307

hbu@chronixbiomedical.de

or

Shard Capital Partners LLP

(Corporate Adviser and Broker)

Dr Wang Chong, +44 20 7186 9948

wang.chong@shardcapital.com

or

FTI Consulting

(PR Advisors)

Brett Pollard / Victoria Foster Mitchell / Matthew Moss, +44 20 3727 1000